Japanese researchers have found a piece of the “missing link” about how bone marrow stromal cells restore lost neurologic function when transplanted into animals exhibiting central nervous system disorders, according to a study in the March issue of the Journal of Nuclear Medicine.
“Our study showed that cell transplantation therapy may improve brain receptor function in patients who suffered from cerebral stroke, improving their neurological symptoms,” said Satoshi Kuroda, M.D., Ph.D., who is with the department of neurosurgery at Hokkaido University School of Medicine in Sapporo, Japan. “How the transplanted bone marrow stromal cells restore the lost neurologic function is not clear,” added the co-author of “Improved Expression of ã-Aminobutyric Acid Receptor in Mice With Cerebral Infarct and Transplanted Bone Marrow Stromal Cells: An Autoradiographic and Histologic Analysis.”
What researchers do know is that cells found in an adult’s bone marrow–stromal cells–may provide a safe, ethical source for replacing brain cells lost to neurological disorders such as Alzheimer’s and Parkinson’s diseases. Studies have shown that cells taken from adult human bone marrow may possibly be converted into neural cells–cells with the ability to convert to any type of cell found in the body–that could then be transplanted into the brain.
Using autoradiography (a technique that uses X-ray film to visualize radioactively labeled molecules) and fluorescence immunohistochemistry (the testing of sections of tissue for specific proteins by attaching them with specific antibodies), the researchers examined the binding of a radioactive molecule with a specific receptor protein in animals with cerebral infarcts or strokes. Their findings “clearly showed” that bone marrow stromal cells “may contribute to neural tissue regeneration by migrating toward the periinfarct area and acquiring the neuron-specific receptor function,” reports the JNM article.
The authors emphasized that “it is essential to clarify the underlying mechanism before undertaking clinical trials with stem cells’“based approaches for patients with cerebral stoke.” Their results “may help fill in a piece of the ‘missing link’ between histologic findings and functional recovery in animal experiments and may be useful for further stem cell research.” More research needs to be done “to fully clarify the mechanism of cell transplantation therapy for neurological disorders,” said Kuroda. He added, “When the efficacy, mechanism and safety of cell transplantation therapy are established, we will be able to apply it to clinical situations.”
Molecular imaging and nuclear medicine are useful tools that allow the visualization of different kinds of neuronal functions to evaluate cell transplantation therapy in both experimental and clinical situations, said Kuroda. “It is very difficult to visualize neuronal functions; therefore, we chose receptor imaging to assess the effects of cell transplantation therapy on cerebral stroke,” he explained.
Besides Kuroda, co-authors of “Improved Expression of ã-Aminobutyric Acid Receptor in Mice With Cerebral Infarct and Transplanted Bone Marrow Stromal Cells: An Autoradiographic and Histologic Analysis” include Hideo Shichinohe, M.D., Ph.D., Shunsuke Yano, M.D., Ph.D., Kazutoshi Hida, M.D., Ph.D., and Yoshinobu Iwasaki, M.D., Ph.D., all with the department of neurosurgery at Hokkaido University Graduate School of Medicine in Sapporo, Japan; and Takako Ohnishi, MSc, and Hiroshi Tamagami, MSc, both in the research and development division, Research Center, Nihon Medi-Physics Co. Ltd., Sodegaura, Japan.
###
Media representatives: To obtain a copy of this article and related images, please contact Maryann Verrillo by phone at (703) 708-9000, ext. 1211, or send an e-mail to mverrillo@snm.org. Current and past issues of the Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org/. Print copies can be obtained by contacting the SNM Service Center, Society of Nuclear Medicine, 1850 Samuel Morse Drive, Reston, VA 20190-5316; phone (800) 513-6853; e-mail servicecenter@snm.org; fax (703) 708-9015. A subscription to the journal is an SNM member benefit.
About SNM
SNM is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of molecular and nuclear imaging to diagnose, manage and treat diseases in women, men and children. Founded more than 50 years ago, SNM continues to train physicians, technologists, scientists, physicists, chemists and radiopharmacists in state-of-the-art imaging procedures and advances; provide essential resources for health care practitioners and patients; publish the most prominent peer-reviewed resource in the field; sponsor research grants, fellowships and awards; and host the premier annual meeting for medical imaging. SNM members have introduced–and continue to explore–biological and technological innovations in medicine that noninvasively investigate the molecular basis of diseases, benefiting countless generations of patients. SNM is based in Reston, Va.; additional information can be found online at http://www.snm.org/
Contact: Maryann Verrillo
mverrillo@snm.org
